The National Institute for Health and Care Excellence (NICE) has recommended Rhythm Pharmaceuticals’ Imcivree (setmelanotide) as a treatment for hyperphagia (insatiable hunger) and early onset severe obesity.
The recommendation follows positive results from clinical trials suggesting that Imcivree may reduce weight and body mass index (BMI) in people with obesity caused by POMC and LEPR deficiencies, with an improvement in hunger and quality of life also evidenced as a result of the treatment.